SIMPONI® offers an injection experience to consider for your patients1,2

SIMPONI® has half the injections of Humira®1,2

Half The DosesHalf The Doses

This is not intended to compare the safety, effectiveness, or uses of these treatments. Please refer to each product’s Prescribing Information for recommended dosing and administration. Humira® is a registered trademark of AbbVie Inc.

The SmartJect® autoinjector: designed to keep the needle out of sight

Autoinjector Features
Autoinjector Features

SIMPONI® is intended for use under the guidance and supervision of a physician. Patients may self-inject SIMPONI® after physician approval and proper training.

Prior to initiating SIMPONI® and periodically during therapy, patients should be evaluated for active tuberculosis and tested for latent infection. Prior to initiating SIMPONI®, patients should be tested for hepatitis B viral infection.

Injection-site reactions

In the PURSUIT Induction study, 3.4% of SIMPONI®-treated patients (n=25/734) reported injection-site reactions vs 1.5% of placebo patients (n=5/330). Injection-site reactions included redness, swelling, itching, pain, bruising, and tingling.1,3

Most common adverse reactions are upper respiratory tract infection, nasopharyngitis, and injection-site reactions.

References: 1. SIMPONI® (golimumab) Prescribing Information. Janssen Biotech, Inc. 2. HUMIRA® (adalimumab) Prescribing Information. AbbVie Inc. 3. Sandborn WJ, Feagan BG, Marano C, et al; PURSUIT-SC Study Group. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:85-95.